Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release

Thrombosis Research

Volumn 124, Issue 2, 2009, Pages 199-207

  Liu, Fu Chao ^a,b   Liao, Chang Hui ^b   Chang, Yao Wen ^a   Liou, Jiin Tarng ^a,b   Day, Yuan Ji ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

cAMP phosphodiesterase; Platelet aggregation; Splitomicin

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; CYCLIC AMP PHOSPHODIESTERASE; IMIDAZOLE; INDOMETACIN; ISOBUTYLMETHYLXANTHINE; NAPHTHOL DERIVATIVE; PROSTAGLANDIN E1; SPLITOMICIN; THROMBIN; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

CALCIUM; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; NAPHTHALENES; PHOSPHORIC DIESTER HYDROLASES; PLATELET AGGREGATION; PYRONES; TIME FACTORS;

EID: 67349272779     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.02.013     Document Type: Article

References (54)

1. Posakony J., Hirao M., Stevens S., Simon J.A., and Bedalov A. Inhibitors of Sir2: evaluation of splitomicin analogues. J Med Chem 47 (2004) 2635-2644
2. Kruszewski M., and Szumiel I. Sirtuins (histone deacetylases III) in the cellular response to DNA damage-facts and hypotheses. DNA Repair (Amst) 4 (2005) 1306-1313
3. North B.J., and Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 5 (2004) 224
4. Frye R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 260 (1999) 273-279
5. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 444 (2006) 868-874
6. Haigis M.C., and Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 20 (2006) 2913-2921
7. Longo V.D., and Kennedy B.K. Sirtuins in aging and age-related disease. Cell 126 (2006) 257-268
8. Ko F.N., Sheu S.J., Liu Y.M., Huang T.F., and Teng C.M. Inhibition of rabbit platelet aggregation by 1,4-naphthoquinones. Thromb Res 57 (1990) 453-463
9. Jin Y.R., Ryu C.K., Moon C.K., Cho M.R., and Yun Y.P. Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation. Pharmacology 70 (2004) 195-200
10. Shen A.Y., Huang M.H., Teng C.M., and Wang J.S. Inhibition of 2-P-mercaptophenyl-1,4-naphthoquinone on human platelet function. Life Sci 65 (1999) 45-53
11. Zhang Y., Adachi M., Zou H., Hareyama M., Imai K., and Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys 65 (2006) 859-866
12. Kim I.A., Shin J.H., Kim I.H., Kim J.H., Kim J.S., Wu H.G., Chie E.K., Ha S.W., Park C.I., and Kao G.D. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 12 (2006) 940-949
13. Neugebauer R.C., Uchiechowska U., Meier R., Hruby H., Valkov V., Verdin E., Sippl W., and Jung M. Structure-Activity Studies on Splitomicin Derivatives as Sirtuin Inhibitors and Computational Prediction of Binding Mode. J Med Chem 51 (2008) 1203-1213
14. Willoughby S., Holmes A., and Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 1 (2002) 273-288
15. Gregg D., and Goldschmidt-Clermont P.J. Cardiology patient page. Platelets and cardiovascular disease. Circulation 108 (2003) e88-e90
16. Shimizu M., Kohara S., Yamamoto M., Ando Y., Haida M., and Shinohara Y. Significant relationship between platelet activation and intra-media thickness of the carotid artery in patients with ischemic cerebrovascular disease. Thromb Res 117 (2006) 647-652
17. Hoogendijk E.M., Jenkins C.S., van Wijk E.M., Vos J., and ten Cate J.W. Spontaneous platelet aggregation in cerebrovascular disease II. Further characterisation of the platelet defect. Thromb Haemost 41 (1979) 512-522
18. von H.P., and Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100 (2007) 27-40
19. Harker L.A., Ross R., and Glomset J. Role of the platelet in atherogenesis. Ann N Y Acad Sci 275 (1976) 321-329
20. Freson K., Thys C., Wittevrongel C., and Van G.C. Mechanisms of action and targets for actual and future antiplatelet drugs. Mini Rev Med Chem 6 (2006) 719-726
21. Born G., and Patrono C. Antiplatelet drugs. Br J Pharmacol 147 Suppl 1 (2006) S241-S251
22. Hankey G.J., and Eikelboom J.W. Antiplatelet drugs. Med J Aust 178 (2003) 568-574
23. Joseph J.E., and Machin S.J. New antiplatelet drugs. Blood Rev 11 (1997) 178-190
24. Gerrard J.M. Platelet aggregation. cellular regulation and physiologic role. Hosp Pract (Off Ed) 23 89-4 (1988) 107
25. Mustard J.F., Packham M.A., and Kinlough-Rathbone R.L. Platelets, blood flow, and the vessel wall. Circulation 81 (1990) I24-I27
26. Tobelem G. Mechanism of platelet aggregation and mode of action of platelet antiaggregants. Rev Prat 39 (1989) 2219-2222
27. Booyse F.M., and Rafelson Jr. M.E. Regulation and mechanism of platelet aggregation. Ann N Y Acad Sci 201 (1972) 37-60
28. Hettasch J.M., and Le Breton G.C. Modulation of Ca2+ fluxes in isolated platelet vesicles: effects of cAMP-dependent protein kinase and protein kinase inhibitor on Ca2+ sequestration and release. Biochim Biophys Acta 931 (1987) 49-58
29. Wang T.Y., Hussey C.V., Sasse E.A., and Fobian J.E. Human platelet aggregation and cAMP system-cAMP level, adenyl cyclase, phosphodiesterase. Ann Clin Lab Sci 8 (1978) 403-412
30. Demolis J.L., Robert A., Mouren M., Funck-Brentano C., and Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol 22 (1993) 711-716
31. Katsube N., Sakaguchi K., Fujitani B., and Aishita H. Anti-platelet and anti-thrombotic effects of OP-41483.alpha-CD, a prostacyclin analogue, in experimental animals. Prostaglandins Leukot Essent Fatty Acids 49 (1993) 795-804
32. Boullin D.J., Green A.R., and Price K.S. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1. J Physiol 221 (1972) 415-426
33. Rajtar G., Cerletti C., Castagnoli M.N., Bertele V., and de G.G. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. Biochem Pharmacol 34 (1985) 307-310
34. Wallis R.B., and Zelaschi D. Differential effects of cyclo-oxygenase inhibitors and thromboxane synthase inhibitors on rabbit platelet aggregation: evidence for the importance of prostaglandin endoperoxides as mediators in arachidonate-induced aggregation but not in collagen-induced aggregation. Biochem Soc Trans 8 (1980) 726-727
35. Kimura Y., and Yasunaga K. Interaction of prostaglandin and cyclic AMP involved in regulation of platelet function. Nippon Ketsueki Gakkai Zasshi 43 (1980) 1130-1138
36. Salzman E.W. Cyclic AMP and platelet function. N Engl J Med 286 (1972) 358-363
37. Cole B., Robison G.A., and Hartmann R.C. The role of cyclic AMP in platelet function. Ann N Y Acad Sci 185 (1971) 477-487
38. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 69 (1989) 58-178
39. Geiger J., Nolte C., Butt E., Sage S.O., and Walter U. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci U S A 89 (1992) 1031-1035
40. Rhee S.G., Lee C.W., and Jhon D.Y. Phospholipase C isozymes and modulation by cAMP-dependent protein kinase. Adv Second Messenger Phosphoprotein Res 28 (1993) 57-64
41. Feijge M.A., Ansink K., Vanschoonbeek K., and Heemskerk J.W. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem Pharmacol 67 (2004) 1559-1567
42. Hirose H., Mashiko S., Kimura T., Ishida F., Mochizuki N., Nishibe T., and Nishikibe M. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects. J Cardiovasc Pharmacol 35 (2000) 586-594
43. Sun B., Le S.N., Lin S., Fong M., Guertinin M., Liu Y., Tandon N.N., Yoshitake M., and Kambayashi J. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol 40 (2002) 577-585
44. Jackson S.P., Nesbitt W.S., and Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 1 (2003) 1602-1612
45. Kang W.S., Chung K.H., Chung J.H., Lee J.Y., Park J.B., Zhang Y.H., Yoo H.S., and Yun Y.P. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J Cardiovasc Pharmacol 38 (2001) 875-884
46. Shah B.H., Nawaz Z., Pertani S.A., Roomi A., Mahmood H., Saeed S.A., and Gilani A.H. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol 58 (1999) 1167-1172
47. Lazarowski E.R., and Lapetina E.G. Activation of platelet phospholipase C by fluoride is inhibited by elevation of cyclic AMP. Biochem Biophys Res Commun 158 (1989) 440-444
48. Feoktistov I.A., Paul S., Hollister A.S., Robertson D., and Biaggioni I. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation. Am J Hypertens 5 (1992) 147S-153S
49. Bell R.L., Kennerly D.A., Stanford N., and Majerus P.W. Diglyceride lipase: a pathway for arachidonate release from human platelets. Proc Natl Acad Sci U S A 76 (1979) 3238-3241
50. Billah M.M., Lapetina E.G., and Cuatrecasas P. Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets. J Biol Chem 256 (1981) 5399-5403
51. Xing M., Post S., Ostrom R.S., Samardzija M., and Insel P.A. Inhibition of phospholipase A2-mediated arachidonic acid release by cyclic AMP defines a negative feedback loop for P2Y receptor activation in Madin-Darby canine kidney D1 cells. J Biol Chem 274 (1999) 10035-10038
52. Minkes M., Stanford N., Chi M.M., Roth G.J., Raz A., Needleman P., and Majerus P.W. Cyclic adenosine 3′,5′-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J Clin Invest 59 (1977) 449-454
53. Lapetina E.G. Incorporation of synthetic 1,2-diacylglycerol into platelet phosphatidylinositol is increased by cyclic AMP. FEBS Lett 195 (1986) 111-114
54. Lerea K.M., Glomset J.A., and Krebs E.G. Agents that elevate cAMP levels in platelets decrease thrombin binding. J Biol Chem 262 (1987) 282-288